标题
Targeting the complexity of ERBB2 biology in gastroesophageal carcinoma
作者
关键词
-
出版物
ANNALS OF ONCOLOGY
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2022-08-11
DOI
10.1016/j.annonc.2022.08.001
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial
- (2022) Eva Versteijne et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial
- (2022) Howard P Safran et al. LANCET ONCOLOGY
- Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
- (2022) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy
- (2022) Dina V. Hingorani et al. Nature Communications
- A multi-institutional phase Ib/II trial of first-line triplet regimen (Pembrolizumab, Trastuzumab, Chemotherapy) for HER2-positive advanced gastric and gastroesophageal junction cancer (PANTHERA Trial): Molecular profiling and clinical update.
- (2021) Sun Young Rha et al. JOURNAL OF CLINICAL ONCOLOGY
- Claudin 18.2 – a FAST-moving target in gastric cancer?
- (2021) A. Athauda et al. ANNALS OF ONCOLOGY
- HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study
- (2021) Ivonne Haffner et al. JOURNAL OF CLINICAL ONCOLOGY
- Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
- (2021) Nancy Y Lee et al. LANCET ONCOLOGY
- The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
- (2021) Yelena Y. Janjigian et al. NATURE
- A population-based study on intestinal and diffuse type adenocarcinoma of the oesophagus and stomach in the Netherlands between 1989 and 2015
- (2020) Rosa T. van der Kaaij et al. EUROPEAN JOURNAL OF CANCER
- Identification of Subtypes of Barrett’s Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome Data
- (2020) SriGanesh Jammula et al. GASTROENTEROLOGY
- A phase Ib study of nivolumab plus trastuzumab with S-1/capecitabine plus oxaliplatin for HER2-positive advanced gastric cancer (Ni-HIGH study): Safety evaluation.
- (2020) Daisuke Takahari et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II study of efficacy and safety of RC48-ADC in patients with locally advanced or metastatic HER2-overexpressing gastric or gastroesophageal junction cancers.
- (2020) Zhi Peng et al. JOURNAL OF CLINICAL ONCOLOGY
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
- (2020) Sandra M Swain et al. LANCET ONCOLOGY
- First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
- (2020) Yelena Y Janjigian et al. LANCET ONCOLOGY
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
- (2020) Kohei Shitara et al. NEW ENGLAND JOURNAL OF MEDICINE
- An Integrative Morphomolecular Classification System of Gastric Carcinoma With Distinct Clinical Outcomes
- (2020) Jia-Huei Tsai et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers
- (2020) Soo-Chin Lee et al. CLINICAL CANCER RESEARCH
- Antibody–drug conjugates to treat gastric cancer
- (2020) Shigehiro Koganemaru et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Evaluation of Next Generation Sequencing for Detecting HER2 Copy Number in Breast and Gastric Cancers
- (2020) Dongfeng Niu et al. PATHOLOGY & ONCOLOGY RESEARCH
- Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy
- (2020) Christopher A Chuckran et al. Journal for ImmunoTherapy of Cancer
- Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer
- (2020) Kohei Yamashita et al. BRITISH JOURNAL OF CANCER
- MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma
- (2020) Daniel VT Catenacci et al. Future Oncology
- HER2 testing in gastric cancer diagnosis: insights on variables influencing HER2-positivity from a large, multicenter, observational study in Germany
- (2019) Gustavo Baretton et al. VIRCHOWS ARCHIV
- The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic
- (2019) Alexander M. Frankell et al. NATURE GENETICS
- [fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification
- (2019) Naoki Takegawa et al. INTERNATIONAL JOURNAL OF CANCER
- Tumor Heterogeneity Index to Detect HER2 Amplification by Next-Generation Sequencing
- (2019) Sangjoon Choi et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- HER2-targeted therapies — a role beyond breast cancer
- (2019) Do-Youn Oh et al. Nature Reviews Clinical Oncology
- Boosting therapeutic potency of antibodies by taming Fc domain functions
- (2019) Tae Hyun Kang et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985)
- (2019) Zhuyu Xu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
- (2019) Rashmi K. Murthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients
- (2018) S T Kim et al. ANNALS OF ONCOLOGY
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
- (2018) Antonio C. Wolff et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion
- (2018) Bharat K.R. Chaganty et al. CANCER LETTERS
- Incidence Trends of Esophageal and Gastric Cancer Subtypes by Race, Ethnicity, and Age in the United States, 1997–2014
- (2018) Farhad Islami et al. Clinical Gastroenterology and Hepatology
- Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer
- (2018) De-Shen Wang et al. GUT
- Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study
- (2018) Josep Tabernero et al. LANCET ONCOLOGY
- Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604)
- (2018) Hiroshi Saeki et al. EUROPEAN JOURNAL OF CANCER
- Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3)
- (2018) Seyoung Seo et al. Gastric Cancer
- Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial
- (2018) Maura L Gillison et al. LANCET
- EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer
- (2018) Francisco Sanchez-Vega et al. Cancer Discovery
- Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status
- (2017) Dara S. Ross et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Pharmacokinetics, Biodistribution, and Radiation Dosimetry for89Zr-Trastuzumab in Patients with Esophagogastric Cancer
- (2017) Joseph A. O'Donoghue et al. JOURNAL OF NUCLEAR MEDICINE
- A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion
- (2017) Christiane Daniela Fichter et al. JOURNAL OF PATHOLOGY
- Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
- (2017) Peter C Thuss-Patience et al. LANCET ONCOLOGY
- Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
- (2017) Toshihiko Doi et al. LANCET ONCOLOGY
- Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
- (2017) Véronique Diéras et al. LANCET ONCOLOGY
- FcγRIIA and IIIA polymorphisms predict clinical outcome of trastuzumab-treated metastatic gastric cancer
- (2017) De-shen Wang et al. OncoTargets and Therapy
- Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer
- (2017) Yelena Y. Janjigian et al. Cancer Discovery
- Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma
- (2017) Eirini Pectasides et al. Cancer Discovery
- Oesophageal cancer
- (2017) Elizabeth C. Smyth et al. Nature Reviews Disease Primers
- HER2Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology
- (2016) Angela N. Bartley et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Toxicities of chimeric antigen receptor T cells: recognition and management
- (2016) Jennifer N. Brudno et al. BLOOD
- Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
- (2016) Yusuke Ogitani et al. CANCER SCIENCE
- Bifunctional αHER2/CD3 RNA-engineered CART-like human T cells specifically eliminate HER2+ gastric cancer
- (2016) Feifei Luo et al. CELL RESEARCH
- Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer
- (2016) V. Varadan et al. CLINICAL CANCER RESEARCH
- Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer
- (2015) C.-Y. Ock et al. CLINICAL CANCER RESEARCH
- Global patterns of cardia and non-cardia gastric cancer incidence in 2012
- (2015) A Colquhoun et al. GUT
- Trastuzumab Triggers Phagocytic Killing of High HER2 Cancer Cells In Vitro and In Vivo by Interaction with Fcγ Receptors on Macrophages
- (2015) Yun Shi et al. JOURNAL OF IMMUNOLOGY
- Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
- (2015) Razvan Cristescu et al. NATURE MEDICINE
- Clinicopathological Variation of Lauren Classification in Gastric Cancer
- (2015) Yun-Chi Chen et al. PATHOLOGY & ONCOLOGY RESEARCH
- Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer
- (2015) E. L. Kwak et al. Cancer Discovery
- HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
- (2014) Eric Van Cutsem et al. Gastric Cancer
- Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma
- (2014) Jihun Kim et al. JOURNAL OF CLINICAL INVESTIGATION
- Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment ofHER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
- (2014) Taroh Satoh et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive molecular characterization of gastric adenocarcinoma
- (2014) Adam J. Bass et al. NATURE
- Level ofHER2Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab
- (2013) Carlos Gomez-Martin et al. JOURNAL OF CLINICAL ONCOLOGY
- Monitoring Afatinib Treatment in HER2-Positive Gastric Cancer with 18F-FDG and 89Zr-Trastuzumab PET
- (2013) Y. Y. Janjigian et al. JOURNAL OF NUCLEAR MEDICINE
- A Novel Proteomics-Based Clinical Diagnostics Technology Identifies Heterogeneity in Activated Signaling Pathways in Gastric Cancers
- (2013) Jeeyun Lee et al. PLoS One
- Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers
- (2011) R. Ghosh et al. CANCER RESEARCH
- IL-12 Enhances the Antitumor Actions of Trastuzumab via NK Cell IFN- Production
- (2011) A. C. Jaime-Ramirez et al. JOURNAL OF IMMUNOLOGY
- Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+breast cancer patients
- (2011) Maurizio Scaltriti et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Fc R2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer
- (2010) K. Tamura et al. ANNALS OF ONCOLOGY
- Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo
- (2010) Z. A. Wainberg et al. CLINICAL CANCER RESEARCH
- Tumor Antigen–Targeted, Monoclonal Antibody–Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape
- (2010) Robert L. Ferris et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
- (2008) C. Gravalos et al. ANNALS OF ONCOLOGY
- Assessment of a HER2 scoring system for gastric cancer: results from a validation study
- (2008) M Hofmann et al. HISTOPATHOLOGY
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer
- (2008) Antonino Musolino et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search